MISC

2002年

Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer

Diseases of the Colon and Rectum
  • Takeyoshi Yamauchi
  • ,
  • Masahiko Watanabe
  • ,
  • Tetsuro Kubota
  • ,
  • Hirotoshi Hasegawa
  • ,
  • Yoshiyuki Ishii
  • ,
  • Takashi Endo
  • ,
  • Yasuo Kabeshima
  • ,
  • Kyoko Yorozuya
  • ,
  • Kentaro Yamamoto
  • ,
  • Makio Mukai
  • ,
  • Masaki Kitajima

45
1
開始ページ
98
終了ページ
103
記述言語
英語
掲載種別
DOI
10.1007/s10350-004-6120-5

PURPOSE: Epidemiologic studies indicate that the use of nonsteroidal anti-inflammatory drugs, which inhibit cyclooxygenase activity, reduce the risk of colorectal cancer. In addition, several studies demonstrate increased expression of cyclooxygenase-2 in human colorectal cancer tissues. However, the role of cyclooxygenase-2 expression in colorectal cancer has not yet been fully established. The aim of this study was to clarify the clinicopathologic significance of cyclooxygenase-2 expression in human colorectal cancer. METHODS: A total of 232 surgically resected colorectal cancer specimens were analyzed immunohistochemically with the use of a murine anti-human cyclooxygenase-2 monoclonal antibody. Cyclooxygenase-2 expression was then compared with clinicopathologic background and survival outcome. RESULTS: Cyclooxygenase-2 was expressed in the cytoplasm of the cancer cells but not in normal epithelium. Cyclooxygenase-2 expression was noted in 71.6 percent (166/232) of the cancer patients and correlated significantly with histologic type (P = 0.033), depth of invasion (P = 0.016), pathologic stage (P = 0.020), and metachronous liver metastasis (P = 0.001). Multivariate analysis for factors associated with metachronous liver metastasis showed that cyclooxygenase-2 expression was one of the independent risk factors, second only to lymph node metastasis. Patients with cyclooxygenase-2 expression showed a significantly poorer outcome compared with those without cyclooxygenase-2 expression (P = 0.002). CONCLUSION: Cyclooxygenase-2 expression in the primary lesion may be a useful marker for evaluating prognosis and liver metastasis in patients with colorectal cancer.

リンク情報
DOI
https://doi.org/10.1007/s10350-004-6120-5
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/11786771
ID情報
  • DOI : 10.1007/s10350-004-6120-5
  • ISSN : 0012-3706
  • PubMed ID : 11786771
  • SCOPUS ID : 18244401954

エクスポート
BibTeX RIS